2011 News Releases

iCo Therapeutics CEO to Present at the Ophthalmology Innovation Summit

For Immediate Release                                                                            October 20, 2011

VANCOUVER, CANADA - iCo Therapeutics Inc. (TSX-V “ICO”) today announced that Andrew Rae, iCo’s President & CEO, will provide a corporate update at the Ophthalmology Innovation Summit (OIS). Mr. Rae’s presentation will take place today at 8:46 am EST, Thursday October 20th, 2011 at the Rosen Plaza Hotel in Orlando, FL. 

The OIS is a premier ophthalmology conference that seeks to unite leaders in the development of ophthalmic products, drugs, and devices. For more information please refer to:  http://www.ophthalmologysummit.com/.

No regulatory authority has approved or disapproved the content of this release.  The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Forward Looking Statements

Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on iCo Therapeutics’ current beliefs as well as assumptions made by and information currently available to iCo Therapeutics and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.  Due to risks and uncertainties, including the risks and uncertainties identified by iCo Therapeutics in its public securities filings; actual events may differ materially from current expectations. iCo Therapeutics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

Copyright 2015 ICO Therapeutics | Disclaimer